drugset / Trial / NCT00777868

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis

NCT00777868

Phase 2 Completed 135 enrolled Dow Pharmaceutical Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and effectiveness of two concentrations of IDP-108 in treating patients with onychomycosis

Timeline

Start
2007-10
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Efinaconazole Small molecule 5 % Topical
Subject Efinaconazole Small molecule 10 % Topical

Indications